Clinical outcomes of linezolid and vancomycin in patients with nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus stratified by baseline renal function: a retrospective, cohort analysis

Table 2 Differences in clinical and microbiological successes and nephrotoxicity by treatment and baseline renal function in mITT patients

Parameter	Baseline renal function strata^a,b	Linezolid n/N (%)^c	Vancomycin n/N (%)^c	Absolute risk differences in success/toxicity rates % (95% CI)^c
Clinical Success at EOT	All mITT patients	161/201 (80)	145/214 (68)	12.3 (4.0, 20.7)*
	Normal	99/117 (85)	65/95 (68)	16.2 (4.8, 27.6)*
	Mild/moderate impairment	48/63 (76)	53/77 (69)	7.4 (−7.4, 22.1)
	Severe impairment	5/7 (71)	10/15 (67)	4.8 (−36.3, 45.9)
Clinical Success at EOS	All mITT patients	102/186 (55)	92/205 (45)	10.0 (0.1, 19.8)*
	Normal	65/108 (60)	44/92 (48)	12.4 (−1.4, 26.1)
	Mild/moderate impairment	29/59 (49)	32/73 (44)	5.3 (−11.8, 22.4)
	Severe impairment	4/8 (50)	5/13 (38)	11.5 (−32.0, 55.1)
Microbiological Success at EOT	All mITT patients	161/203 (79)	127/218 (58)	21.1 (12.5, 29.7)*
	Normal	93/117 (80)	56/96 (58)	21.2 (8.9, 33.4)*
	Mild/moderate impairment	50/65 (77)	44/79 (56)	21.2 (6.2, 36.2)*
	Severe impairment	5/7 (71)	11/15 (73)	−1.9 (−42.2, 38.4)
Microbiological Success at EOS	All mITT patients	111/195 (57)	96/209 (46)	11.0 (1.3, 20.7)*
	Normal	67/111 (60)	44/95 (46)	14.0 (0.5, 27.6)*
	Mild/moderate impairment	33/65 (51)	36/74 (49)	2.1 (−14.5, 18.8)
	Severe impairment	5/8 (63)	5/13 (38)	24.0 (−18.7, 66.8)
Occurrence of acute kidney injury (AKI)	All mITT patients	18/214 (8)	39/214 (18)	−9.8 (−16.2, −3.4)*
	Normal	14/126 (11)	21/99 (21)	−10.1 (−19.8, −0.4)*
	Mild/moderate impairment	5/71 (7)	13/78 (17)	−9.6 (−19.8, 0.6)
	Severe impairment	0/8 (0)	3/15 (20)	−20.0 (−40.2, 0.2)

EOT end of treatment, EOS end of study, CI confidence interval
*P-value <0.05, which was based on Chi-square test or Fisher Exact test
^aEstimated creatinine clearance for renal function was assessed as a categorical variable: normal = >80 ml/min, mild/moderate impairment = 30–80 ml/min, and severe impairment = <30 ml/min
^bThere were 228 patients with normal renal function (linezolid, n = 127; vancomycin, n = 101), 152 patients with mild/moderate renal impairment (linezolid, n = 73; vancomycin, n = 79), and 25 patients with severe renal impairment (linezolid, n = 9; vancomycin, n = 16)
^cPercentages were calculated excluding missing data in this analysis

ISSN: 1471-2369